Plus Therapeutics announced on May 14, 2025, the presentation of new data on its lead drug REYOBIQ™ from the completed Phase 1 ReSPECT-LM dose escalation trial. The data was presented at the Nuclear Medicine and Neurooncology Conference, held May 9-10, 2025, in Vienna, Austria.
The study highlighted a dose-dependent increase in the average absorbed dose to the cranial and spinal subarachnoid space, reaching 253Gy in Cohort 5. Neuroimaging response data for 16 patients showed five (31%) with a partial response and seven with stable disease, resulting in a Clinical Benefit Rate of 75%.
Additionally, a clinical response based on physician evaluation showed a decrease in disease findings in 14% of evaluable patients and stable findings in 10 patients, for an 86% Clinical Benefit Rate. No dose-limiting toxicity was observed in the first four cohorts, with a Grade 4 DLT in Cohorts 5 and 6. RNA sequencing of LM cells showed early induction of apoptosis, an innate immune response, and an increase in T cells by Day 28.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.